Clinical Immunology Department, Hospital General Universitario Gregorio Marañón, the Immunology Unit, Complutense University, and Instituto para la Investigación Biomédica del Hospital Gregorio Marañón, Madrid, Spain.
J Heart Lung Transplant. 2018 Apr;37(4):439-440. doi: 10.1016/j.healun.2017.08.008. Epub 2017 Aug 19.
In this issue of the Journal of Heart and Lung Transplantation, Marrón-Liñares et al report the results of an interesting study in which they evaluated 51 genes associated with the complement pathway in a small number of heart recipients to explore their relationship with antibody-mediated rejection (AMR). Next-generation sequencing was used in 46 heart transplant recipients (23 with AMR and 23 without AMR). The authors identified a significant association of 2 single-nucleotide polymorphisms with the absence or presence of AMR, respectively, p.Gly54Asp-MBL2 in the mannose-binding lectin (MBL) 2 gene and p.Asn428(p=)-CFP in the alternative complement factor properdin (CFP) gene. This article is a new contribution to the heart transplant literature. It suggests that complement single-nucleotide polymorphisms may influence circulating levels of selected proteins of both the lectin pathway and alternative complement pathways, thus potentially determining which patients will develop AMR.
在本期《心肺移植杂志》中，Marrón-Liñares 等人报告了一项有趣的研究结果。他们在一小部分心脏受者中评估了 51 个与补体途径相关的基因，以探讨其与抗体介导的排斥反应（AMR）的关系。对 46 名心脏移植受者（23 名 AMR 患者和 23 名非 AMR 患者）进行了下一代测序。作者发现，甘露聚糖结合凝集素（MBL）2 基因中的 p.Gly54Asp-MBL2 和备选补体因子properdin（CFP）基因中的 p.Asn428(p=)-CFP 这 2 个单核苷酸多态性与 AMR 的有无分别存在显著相关性。这篇文章是心脏移植文献的新贡献。它表明，补体单核苷酸多态性可能影响凝集素途径和备选补体途径中选定蛋白的循环水平，从而可能决定哪些患者会发生 AMR。
